ARTBIO Appoints Jonathan Freeman Interim Chief Executive Officer

CAMBRIDGE, MA – July 1, 2026 – ARTBIO, Inc. a clinical-stage radiopharmaceutical biotechnology company redefining cancer care, today announced that the Board of Directors has appointed Dr. Jonathan Freeman interim Chief Executive Officer, effective immediately. At the same time, Dr. Emanuele Ostuni has stepped down from his role as Chief Executive Officer.

ARTBIO's core strategic priorities remain entirely unchanged. Dr. Freeman will steer ARTBIO through its next phase of clinical execution, pipeline diversification, and the scaling of its proprietary generator technology and manufacturing network.

“I am honoured to take on the leadership of ARTBIO through its next phase of growth to bring Alpha Radioligand Therapies to patients that need them,” said Jonathan Freeman, Interim CEO of ARTBIO. “On behalf of the entire Company, I want to thank Emanuele for his vision and leadership of ARTBIO over the past four years.”

About ARTBIO

Cancer is relentless. So are we. At ARTBIO, cancer care is redefined by discovering and developing a new class of Alpha Radioligand Therapies (ARTs), powered by unique 212Pb isotope technology and seamless supply. ARTBIO's unique patient-centric framework rests on three pillars: Bringing therapies that matter to patients, scaling a seamless supply and a radiant team to make it all happen. The company is building on a long-standing scientific legacy with nearly a century of pioneering work in radiation therapy conducted at the University of Oslo and Norway's Radium Hospital. For more information, visit www.artbio.com and follow us on LinkedIn.

ARTBIO Media Contact

MDL Strategic Communications
Michael Lauer
michael@mdlcomms.com